Foamix stock: buy or sell?
September 20th, 2019
Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular, rosacea, and other skin conditions in the United States, Germany, and France.
Should I buy Foamix stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Following a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Foamix Pharmaceuticals stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Foamix stock a buy?
Financial institutions and banks post stock ratings everyday.At Stocks2.com, we gathered 3 ratings published for FOMX stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-8-9||Bank of America||n/a||Buy|
Foamix stock analysis
Shares of Foamix Pharmaceuticals stepped up a beatiful 1.40% and closed at $3.62.
Shares of Foamix closed today at $3.62 and stepped up a beatiful 1.40%. Since price and SMA200d lines crossed up on September/5, FOMX climbed $0.54 (17.53%). Since September/13 when SMA50d and SMA100d crossed up, FOMX price gained $0.20 per share (5.85%).
After boosting an amazing 6.00% in a week last week, Foamix Pharmaceuticals closed this week at $3.62 and soared an excellent 3.43%. Late August FOMX plunged a chilling -16.61% in just one week. With this, it's been 3 climbing weeks in a row, soaring a 21.66%.
Early September FOMX price bounced up over the SMA of 40 weeks that acted as support stopping new slides.
Foamix stock price history
Foamix stock went public on September 18th, 2014 with a price of $8.001. Since then, FOMX stock sliced a -54.80%, with a yearly average of -11.00%.
1: Adjusted price after possible price splits or reverse-splits.
Foamix stock historical price chart
FOMX stock reached 52-week highs at $6.20, and all-time highs 2015-05-27 with a price of 14.
Foamix stock price target is $12.00How much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. We have 3 price predictions for FOMX stock published in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-8-9||Bank of America||Reiterates||n/a||$11.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, Foamix Pharmaceuticals presented its financial report, posting an outstanding climb for the Earnings per Share (EPS). Experts expected $-0.26 per share, but Foamix Pharmaceuticals posted $-0.39.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual sales report draw a disappointing loss of -2.02% to $3.60 M USD. When comparing 2018 vs 2017, in contrary, profit margin (that is, the net income divided by revenues) collapsed a -271.86% to -2,062.95%.
|2013||$1.40 M||-||$-2.43 M-173.6%||-|
|2014||$5.41 M||286.71%||$-11.48 M-212.1%||372.59%|
|2015||$0.85 M||-84.32%||$-16.52 M-1945.5%||43.83%|
|2016||$5.53 M||551.00%||$-29.34 M-530.8%||77.61%|
|2017||$3.67 M||-33.62%||$-65.72 M-1791.1%||124.01%|
|2018||$3.60 M||-2.02%||$-74.16 M-2062.9%||12.86%|
Quarterly financial resultsFoamix reported $0.86 million in sales for 2018-Q4, a -0.58% decline compared to previous quarter. Reported quarter earnings marked $-14.08 million with a profit margin of -1,636.98%. Profit margin climbed a 152.62% compared to previous quarter when profit margin was -1,789.60%. When comparing turnover to same quarter last year, Foamix Pharmaceuticals sales marked a frightening decrease and plummed a -17.55%. Looking back to recent quarterly results, Foamix Pharmaceuticals posted 2 negative quarters in a row.
|2017-Q1||$0.93 M||-||$-14.38 M-1551.2%||-|
|2017-Q2||$0.80 M||-13.92%||$-16.39 M-2053.9%||13.98%|
|2017-Q3||$0.90 M||12.91%||$17.58 M1951.5%||-207.28%|
|2017-Q4||$1.04 M||15.76%||$-17.36 M-1664.5%||-198.74%|
|2018-Q1||$0.91 M||-13.14%||$-25.98 M-2867.2%||49.63%|
|2018-Q2||$0.96 M||6.40%||$-18.63 M-1932.4%||-28.29%|
|2018-Q3||$0.87 M||-10.27%||$-15.48 M-1789.6%||-16.90%|
|2018-Q4||$0.86 M||-0.58%||$-14.08 M-1637.0%||-9.06%|
Foamix ownershipWhen you are planning to invest in shares of a company, it's always worth to have a look its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Foamix, 0.70% of all outstanding shares are owned by its staff.
Bearish positions for FOMX stock account 0.00%, no big difference from last month.
For a better understanding, the following table shows ownership data compared to other related stocks:
|Market cap||$220.8 M||$1.8 B|
|Total shares||61.0 M||42.5 M|
|Float shares||35.9 M||31.5 M|
|- Institutional holdings (%)||291.2%||116.2%|
|- Insider holdings (%)||0.7%||2.9%|
|Shares in short selling||0.0%||0.0%|
|Friday, September 20th, 2019|
|Day range||$3.52 - $3.70|
|Average true range||$0.21|
|50d mov avg||$2.84|
|100d mov avg||$2.73|
|200d mov avg||$3.22|
Foamix performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We picked Array as the bechmarking frame for Foamix Pharmaceuticals stock.